Tagged with CAR-T

Opinion Emanuele Ostuni, head of cell & gene therapy for Novartis Oncology in Europe, outlines how stakeholders across the biopharmaceutical value chain can surf the wave of innovation that breakthrough therapies such as CAR-T represent. Waves and Innovation CAR-T therapies are the frontrunners of a wave of amazing biomedical innovation Over…

Cell & Gene Therapy Medicare, a national health insurance program in the United States covering Americans aged 65 and older as well as younger people with disabilities, has recently announced it will be increasing reimbursement rates and expanding coverage for cell and gene therapy treatments, good news for cancer patients and pharma companies Gilead…

Opinion Pierre Meulien of the Innovative Medicines Initiative (IMI) highlights why cell and gene therapies seem finally braced for mainstream adoption as well as the significant barriers that still need to be overcome for large patient numbers to access these innovative and often costly treatments.   Today, [ATMPs] finally seem to…

Spain Stefanie Granado, director general of Takeda Iberia recounts the opportunities available for Takeda in Spain following its acquisition of Shire. She also discusses Takeda’s local acquisition of TiGenix, handing Takeda stem cell production capabilities, and how this makes Spain a key market and hub for the company.   We continue…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in the cell and gene therapy market for investments and deal activities.   Background Cell and gene therapies hold the promise of bringing significant clinical benefits to patients by directly targeting the underlying cause of disease. With tremendous…

Janssen In this exclusive and wide-ranging interview, Janssen’s EMEA head Kris Sterkens outlines the company’s strategies in Europe, its increasing embrace of digital solutions, and the shift toward pre-emptive and precision treatments. Sterkens also highlights how Janssen is positioning itself in the emerging markets under his remit and how the ongoing…

Taiwan Grace Yeh, president and founder of PharmaEngine, gives an update on the company’s recent growth and development of their second nanomedicine cancer treatment. Yeh goes on to explain the unique positioning of nanomedicine within oncology and Taiwan’s role as an active participant in the global fight against cancer.   PharmaEngine…

China William Wei Cao, chairman and CEO of Gracell, shares the fascinating journey that inspired him to establish Gracell in Shanghai to tackle the four big challenges facing the global CAR-T industry; the four novel technology platforms Gracell is working on that are already drawing significant investor and Big Pharma interest;…

France André Choulika, Chairman and CEO of Cellectis, discusses how UCART will revolutionize cell therapy as a universal gene-edited solution as opposed to the current therapies on the market which uses a patient’s own re-engineered T-cells. Choulika goes on to share how the company is positioning itself for its anticipated commercialization…

France Denis Delval, CEO of iconic French pharma firm LFB since December 2017, discusses his key priorities to build the new LFB.   My vision is that we should be strong enough to assume a leadership position in any space that we seek to participate in During his two terms at…

Pharma André Choulika, founder & CEO of Cellectis, reveals why the 21st century will be the century of gene editing and Cellectis will be one of the leaders of this revolution; how unlike many of their competitors, they are a gene editing company at the core and why the idea of…